Systematic optimization of a lead-structure identities for a selective short peptide agonist for the human orphan receptor BRS-3

Journal of Peptide Science

Volumn 8, Issue 8, 2002, Pages 461-475

  Weber, Dirk ^a   Berger, Claudia ^b   Heinrich, Timo ^b   Eickelmann, Peter ^b   Antel, Jochen ^b   Kessler, Horst ^a,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Solvay Pharmaceuticals GmbH   (Germany)

^c NONE   (Germany)

Author keywords

BRS 3 ligands; Orphan receptor; Selective short peptide agonist; Tetrapeptide mini library

Indexed keywords

AMINO ACID; BETA ALANINE; BOMBESIN DERIVATIVE; BOMBESIN RECEPTOR; BOMBESIN[6-13][DEXTRO 6 PHENYLALANINE 13 PHENYLALANINE]PROPYLAMIDE; BOMBESIN[6-14][DEXTRO 6 PHENYLALANINE 11 BETA ALANINE 13 PHENYLALANINE 14 LEUCINE]PROPYLAMIDE; CALCIUM; G PROTEIN COUPLED RECEPTOR; GASTRIN RELEASING PEPTIDE; H DEXTRO PHENYLALANYLGLYCINE DEXTRO TRYPTOPHAN 1 (2 PHENYLETHYL)AMIDE; HISTIDINE; NEUROMEDIN B; PEPTIDE DERIVATIVE; PEPTIDE LIBRARY; PHENYLALANINE; RECEPTOR PROTEIN; RECEPTOR SUBTYPE; TETRAPEPTIDE; TRIPEPTIDE; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG; BOMBESIN; BOMBESIN RECEPTOR SUBTYPE 3; DRUG DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CANCER; CARBOXY TERMINAL SEQUENCE; CHO CELL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; GENE DELETION; GENETIC TRANSFECTION; HUMAN; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN FAMILY; RECEPTOR BINDING; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; DRUG POTENTIATION; HAMSTER; IN VITRO STUDY; RADIOASSAY; SYNTHESIS;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL; BOMBESIN; CHO CELLS; HAMSTERS; HUMAN; IN VITRO; PEPTIDE FRAGMENTS; PEPTIDE LIBRARY; RADIOLIGAND ASSAY; RECEPTORS, BOMBESIN; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; SUPPORT, NON-U.S. GOV'T; ANIMALS; CRICETINAE; HUMANS;

BOVINE RESPIRATORY SYNCYTIAL VIRUS;

EID: 0035993847     PISSN: 10752617     EISSN: None     Source Type: Journal    
DOI: 10.1002/psc.407     Document Type: Article

References (62)

1. BRS-3: A novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells
2. Molecular cloning of a new bombesin receptor subtype expressed in uterus during pregnancy
3. Properties and functions of a neuromedin-B-preferring bombesin receptor in brain microvascular endothelial cells
4. Two distinct receptor subtypes for mammalian bombesin-like peptides
5. Bombesin receptors on gastrin cells
6. Molecular cloning of the bombesin/gastrin-releasing peptide receptor from Swiss 3T3 cells
7. cDNA cloning, characterization, and brain region-specific expression of a neuromedin-B-preferring bombesin receptor
8. Organization and chromosomal localization of the gene for the human bombesin receptor subtype expressed in pregnant uterus
9. Cloning and expression of the neuromedin B receptor and the third subtype of bombesin receptor genes in the mouse
10. The orphan receptor strategy and the discovery of novel neuropeptides
11. Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity
12. Hyperresponsiveness to palatable and aversive taste stimuli in genetically obese (bombesin receptor subtype-3-deficient) mice
13. Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide
14. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer
15. Expression of mRNA for three bombesin receptor subtypes in human bronchial epithelial cells
16. Clinical correlates of bombesin-like peptide receptor subtype expression in human lung cancer cells
17. Targeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice
18. The presence of receptors for bombesin/GRP and mRNA for the three receptor subtypes in human ovarian epithelial cancers
19. Bombesin receptor subtype 3 polynucleotides, polypeptides and ligands for use in treating neurological disorders
20. Discovery of high affinity bombesin receptor subtype 3 agonists
21. Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors
22. Identification of a unique ligand which has high affinity for all four bombesin receptor subtypes
23. Rational design of a peptide agonist that interacts selectively with the orphan receptor, bombesin receptor subtype 3
24. 4-R)
25. Ability of various bombesin receptor agonists and antagonists to alter intracellular signaling of the human orphan receptor BRS-3
26. Identification of four amino acids in the gastrinreleasing peptide receptor that are required for high affinity agonist binding
27. Pharmacology and intracellular signaling mechanisms of the native human orphan receptor BRS-3 in lung cancer cells
28. Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368
29. Covalently cyclized agonist and antagonist analogues of bombesin and related peptides
30. Probing backbone function in bombesin
31. 2 C terminus
32. Bombesin, bombesin analogues and related peptides: Effects on thermoregulation
33. Membrane structure of bombesin studied by infrared spectroscopy. Prediction of membrane interactions of gastrin-releasing peptide, neuromedin B, and neuromedin C
34. Alanine scan and N-methyl amide derivatives of Acbombesin [7-14]
35. Conformation and biological effects of cyclic peptides
36. Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the αvβ3 integrin for a new cancer therapy
37. Relative potency of bombesin-like peptides
38. Discovery of potent and selective peptide agonists at the GRP-preferring bombesin receptor (BB2)
39. 'Peptoid' design
40. The 'peptoid' approach to the design of non-peptide, small molecule agonists and antagonists of neuropeptides
41. Design of non-peptide agonists and antagonists at neuropeptide receptors starting from the chemical structure of neuropeptides
42. Rationally designed 'dipeptoid' analogues of CCK. α-methyltryptophan derivatives as highly selective and highly active gastrin and CCK-B antagonists with potent anxiolytic properties
43. Cholecystokinin dipeptoid antagonists: Design, synthesis and anxiolytic profile of some novel CCK-A and CCK-B selective and 'mixed' CCK-A/CCK-B antagonists
44. Peptoid CCK receptor antagonists: Pharmacological evaluation of CCKA, CCKB and mixed CCKA/B receptor antagonists
45. Second generation 'Peptoid' CCK-B receptor antagonists: Identification and development of N-(adamantyloxycarbonyl)-α-methyl-(R)-trypytophan derivative (CI-1015) with an improved pharmacokinetic profile
46. Somatostatin analogs
47. 2 receptor antagonists
48. 3 receptor selective antagonists
49. 2 receptor antagonist
50. 3 receptor selective antagonists
51. PD 165929 - The first high affinity non-peptide neuromedin-B (NMB) receptor selective antagonist
52. 2) receptor antagonist
53. Solid-phase synthesis of protected peptide fragments using a trialkoxy-diphenyl-methylester resin
54. Solid-phase synthesis of peptides with the highly acid-sensitive HMPB linker
55. Preparation of carboxy-modified peptide fragments using alkoxybenzaldehyde resins
56. A new acid-labile anchor group for the solid-phase synthesis of C-terminal peptide amides by the Fmoc method
57. Preparation of protected peptide fragments using triphenylmethyl resins
58. Solid-phase peptide synthesis utilizing 9-fluorenylmethoxy-carbonyl amino acids
59. Comparison of the peptide structural requirements for high affinity interaction with bombesin receptors
60. Synthesis and biological evaluation of bombesin constrained analogues